Walter E. Washington Convention Center
Washington, D.C.
May 16-19, 2022

NanoView Biosciences Ltd

Brighton,  MA 
United States
http://nanoviewbio.com
  • Booth: 529


The future of virus and exosome characterization is here

NanoView Biosciences is focused on enabling worldwide life science researchers to better understand the biological role of extreacellular vesicles, including exosomes and viral vectors, and their potential use as biomarkers for improving the diagnosis, prognosis, treatment and monitoring of disease. Our proprietary products, including the ExoView platform, have been designed to fully characterize viruses and exosomes for use in research and in the implementation of precision nanomedicine. ExoView is easy to use and does not require purification or large sample volumes.


 Products

  • ExoView R200
    Fully automated, next generation imaging platform that provides a step forward in characterization capabilities within the exosome and virus characterization fields....

  • The next generation imaging platform that provides a step forward in characterization capabilities within the exosome and virus characterization fields.

    For exosomes, the fully automated platform provides multi-level and comprehensive measurements for exosome particle size analysis, exosome concentration, exosome phenotype, and biomarker colocalization. The ExoView platform provides previously unattainable information in a single and bias free sample workflow.

    For viruses, the platform provides rapid and actionable data on virus size, empty/full ratio, viral titer and pseudotype characterization. Data collected using the ExoView platform has been demonstrated to be highly predictive of transduction efficiency, and provides a rapid and predictive tool to assess vector performance at all stages within the purification process.